 CAMBRIDGE, Mass., May 20, 2022 GLOBE NEWSWIRE -- Immuneering Corporation NASDAQ: IMRX, a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today announced that management will present the companys pipeline, platform, and business strategy at the Jefferies Healthcare Conference and the H.C. Wainwright Global Investment Conference, details of which are set forth below. 